Trial Profile
Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (SP0173) in Healthy Adolescents, Adults, and Older Adults
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Mar 2020
Price :
$35
*
At a glance
- Drugs SP 0173 (Primary) ; DTaP vaccine
- Indications Diphtheria; Pertussis; Tetanus
- Focus Adverse reactions; First in man
- Sponsors Sanofi Pasteur
- 28 Jun 2017 Status changed from active, no longer recruiting to completed.
- 17 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 22 Apr 2016 Status changed from active, no longer recruiting to recruiting.